Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs.
<h4>Unlabelled</h4>To understand the development of new psoriasis lesions, we studied a group of moderate-to-severe psoriasis patients who experienced a relapse after ceasing efalizumab (anti-CD11a, Raptiva, Genentech). There were increased CD3(+) T cells, neutrophils, CD11c(+) and CD83(...
Guardado en:
Autores principales: | Leanne M Johnson-Huang, Cara A Pensabene, Kejal R Shah, Katherine C Pierson, Toyoko Kikuchi, Tim Lentini, Patricia Gilleaudeau, Mary Sullivan-Whalen, Inna Cueto, Artemis Khatcherian, Luke A Hyder, Mayte Suárez-Fariñas, James G Krueger, Michelle A Lowes |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3578f6aa939e4e8fb1132dc90435b9aa |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA).
por: Mayte Suárez-Fariñas, et al.
Publicado: (2010) -
Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease.
por: Suyan Tian, et al.
Publicado: (2012) -
Development of novel tDCS stimulation condition to investigate tDCS neurophysiological mechanisms
por: Silke Kerstens, et al.
Publicado: (2021) -
Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
por: Mary H. Young, et al.
Publicado: (2021) -
Effects of tDCS and HD-tDCS Enhanced Motor Learning on Robotic TMS Motor Maps in Children
por: Adrianna Giuffre, et al.
Publicado: (2021)